ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) closed its last session at $11.01 with the change of +3.48%. The market capitalization of the company is $2.12B with an average Volume of 4.83 million shares. The stock currently has its 52-Week High range of $11.29 and 52-week low range of $4.37. The stock traded total quantity of 9.72 million shares.
Currently ARIAD Pharmaceuticals, Inc. (ARIA) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “4″ Analysts”. “1” rated “Sell” for the company. “3” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $10.13 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $13.00 however minimum price target advised by analysts is $8.00. The Median price target for the stock is measured at $10.00.
Presently, Analysts decided consensus EPS estimate of $-0.20 for present quarter and one month ago projected EPS estimate was at $-0.20. If we take a look at back 3 month ago, consensus EPS estimate was $-0.18.
A current consensus EPS estimate for next quarter is at $-0.18 and 3 month ago EPS forecast was $-0.13. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.17.
For current fiscal year, most recent EPS estimate is set at $-0.09 based on Analyst consensus and three month ago consensus EPS opinions was at $-0.72. During period one month ago, consensus EPS forecast was decided at $-0.08.
A current consensus EPS projection for next fiscal year is observed at $-0.55 and one month ago consensus EPS forecast was at $-0.48. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.43 by analysts.
One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 4 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 3 advised the “Hold” rating about this stock. 1 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 4 said a “Buy Rating” and 0 announced “Overweight Rating”. 3 advised “Hold Rating” regarding the stock. 1 announced “Sell Rating” and 0 disclosed “Underweight Rating”.